Early Trovagene data offer hope for KRAS-mutant colon cancer
Amgen may be leading the race to develop a KRAS inhibitor, but its candidate hasn’t logged the same success in colon cancer as it has in lung cancer. Early data out of the annual meeting of the American Association for Cancer Research (AACR) suggest a different route to treating patients with KRAS-mutated colon cancer—including those with mutations thought to be undruggable.